Loading...
Market
How many additional indications will Lirafugratinib be approved for by end of 2026?
2
Resolution / Starting Odds
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Official announcements from relevant health authorities and Relay Therapeutics
Story
Relay and Elevar Sign Licensing Deal for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma, Potentially Worth $500 Million
Dec 3, 2024, 01:04 PM
Relay Therapeutics and Elevar Therapeutics have entered into an exclusive global licensing agreement for Lirafugratinib, a treatment aimed at FGFR2-driven cholangiocarcinoma and other solid tumors. Under the terms of the agreement, Relay Therapeutics is set to receive up to $500 million in total, which includes $75 million in upfront and regulatory milestone payments, as well as up to $425 million in potential commercial milestone payments and tiered royalties in the low-teens percentage range. This collaboration is expected to enhance Relay's oncology pipeline, particularly in addressing challenging cancer types.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 new indications • 33%
1 new indication • 33%
2 or more new indications • 34%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
None • 33%
1-3 • 33%
More than 3 • 33%
None • 25%
1 additional indication • 25%
2 additional indications • 25%
3 or more additional indications • 25%
Yes • 50%
No • 50%
Approved in the US only • 25%
Approved in the US and EU • 25%
Approved in the US, EU, and other regions • 25%
Not approved in any region • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%